Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia
Eligibility Criteria
Inclusion criteria: Current treatment of at least 3 months with risperidone. Primary diagnosis of schizophrenia. Total Positive and Negative Symptoms Scale (PANSS) score < or = 70 at screening and baseline. Exclusion criteria: Psychiatric diagnosis other than schizophrenia as assessed by the modified Mini International Neuropsychiatric Interview (MINI) and considered by the investigator to be the primary psychiatric diagnosis. History or presence of clinically significant cardiovascular, endocrine, hepatic, renal or other medical disease that might be detrimental to the subject or confound the study. History of any suicide attempt within 3 years of day 1 or significant immediate risk of violence or suicidality.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
A
B